Searched for
GLENMARK RESPIRATORY DRUG
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Glenmark Pharmaceuticals wins USFDA nod for fluticasone inhalerGlenmark Pharmaceuticals has secured a significant approval from the US FDA for its inhaler fluticasone propionate. This marks a key step i...
- Glenmark launches fixed-dose triple therapy for COPDGlenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three...
- Glenmark’s nasal spray Ryaltris gets China’s NMPA nod for allergic rhinitis; to be commercialised by Grand PharmaRyaltris is a fixed-dose combination of olopatadine, an antihistamine and mometasone furoate, a corticosteroid to treat the symptoms of all...
- Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugsGlenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio a...
- US prospects, new drugs make Glenmark look betterGlenmark's marketing portfolio as of December 2024 had 201 generic products authorised for distribution in the US. The company has 51 appli...
- As monsoon sets in, respiratory, malaria drugs see demand riseThe onset of the monsoon in June led to a significant increase in sales of drugs for respiratory, anti-infective, anti-malaria, and gastroi...
- Glenmark bets on respiratory drug, licensing deals to improve businessGlenmark had gross debt of ₹3,765 crore as of June 30, 2022. The company over the years accumulated debt to fund its innovation-led R&D and...
- Glenmark's partner Hikma launches specialty drug Ryaltris in USRyaltris is the only fixed-dose combination of olopatadine hydrochloride and mometasone furoate approved by the USFDA for the treatment of ...
- Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patientsThe Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...
- Glenmark Pharma launches nasal spray Ryaltris in IndiaGlenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost fo...
- Glenmark arm gets Russian health ministry nod for nasal spray RyaltrisIn Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 1...
- Glenmark inks pact with Menarini Group to commercialise nasal spray in EuropeGlenmark Specialty, a Switzerland-based unit of the company, has entered into an exclusive licensing agreement with the Menarini Group for ...
- Glenmark eyes 15% sales growth over 3-5 yearsGlenmark is targeting a consolidated revenue growth of 12-15 per cent over the next 3-5 years.
- Study suggests similarity between biosimilar GBR 310 and omalizumab: GlenmarkGlenmark Pharma said that results from a study suggests similarity between biosimilar GBR 310 and the reference product omalizumab.
- FDA okays Glenmark's first-in-human study for respiratory drugAccording to IMS sales data for the 12-month period ending February 2017, annual sales of XOLAIR 150 mg injection was approximately $1.7 bi...
- Glenmark eyes 20% growth per annum over the next decadeGlenmark Pharmaceuticals aims to keep growing its base business by 18-20 per cent per annum over the next ten years.
- Glenmark Pharmaceuticals inks pact with Celon for generic Seretide AccuhalerAs per the agreement, Glenmark has obtained semi-exclusive marketing and distribution rights of the product across 15 European countries
Load More
